Treating gynecologic malignancies with selective estrogen receptor downregulators (SERDs): promise and challenges

Area of Science:

• Gynecologic Oncology
• Endocrinology
• Pharmacology

Background:

• Endometrial and ovarian cancers are estrogen-dependent, often expressing estrogen receptors (ER).
• Selective estrogen receptor modulators (SERMs) like tamoxifen offer limited benefit in these cancers.
• Selective estrogen receptor downregulators (SERDs), pure ER antagonists, show efficacy in advanced ER-positive breast cancer.

Purpose of the Study:

• To evaluate the potential of SERDs for ER-positive gynecologic malignancies.
• To summarize preclinical and clinical data on SERD efficacy in endometrial and ovarian cancers.
• To highlight the need for predictive biomarkers and further understanding of ER signaling pathways.

Main Methods:

• Review of preclinical and clinical data on SERDs in gynecologic cancers.
• Analysis of estrogen receptor (ER) signaling pathways, including c-Src and other kinases.
• Exploration of potential combination therapies to overcome resistance.

Main Results:

• A subpopulation of patients with endometrial or ovarian cancer may benefit from SERD treatment.
• SERDs represent a promising therapeutic strategy for ER-positive gynecologic malignancies.
• Current data suggest a need for further research into predictive biomarkers and resistance mechanisms.

Conclusions:

• SERDs hold significant potential for treating ER-positive endometrial and ovarian cancers.
• Identification of predictive biomarkers is essential for optimizing SERD therapy.
• Understanding ER signaling and kinase pathways is key to developing effective combination therapies and overcoming resistance.